Literature DB >> 16198245

Circulating levels of myocardial proteins predict future deterioration of congestive heart failure.

Tomonori Sugiura1, Hiroyuki Takase, Takayuki Toriyama, Takatoshi Goto, Ryuzo Ueda, Yasuaki Dohi.   

Abstract

BACKGROUND: This study was designed to test whether circulating levels of myocardium-specific proteins serve as useful markers for the prognosis of patients with congestive heart failure. METHODS AND
RESULTS: Seventy-eight patients with congestive heart failure from dilated cardiomyopathy but in a stable condition were enrolled, and their blood was sampled for measurements of myosin light chain-I (MLC-I), troponin T (TnT), heart fatty-acid-binding protein (H-FABP), and creatine kinase isoenzyme MB (CK-MB). The patients were then followed up for 951 +/- 68 days, with the endpoint being acute deterioration. A univariate analysis revealed that MLC-I, TnT, H-FABP, and CK-MB were significant predictors for acute deterioration of heart failure. Application of the Kaplan-Meier method using cutoff values determined by analysis of receiver operating characteristics curves demonstrated that the incidence of acute deterioration was significantly higher in patients with higher values of MLC-I (61.9%), TnT (52.4%), H-FABP (50.0%), or CK-MB (38.6%) than in those with lower values of these markers (15.8%, 20.4%, 13.6%, and 16.1%, respectively).
CONCLUSIONS: Increased circulating levels of the specific myocardial proteins are related to a higher probability of future acute deterioration of congestive heart failure in patients in a stable condition associated with dilated cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198245     DOI: 10.1016/j.cardfail.2005.04.025

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  12 in total

Review 1.  Treatment strategies for the prevention of heart failure.

Authors:  Justin L Grodin; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2013-12

2.  Myotrophin/V-1 does not act as an extracellular signal to induce myocyte hypertrophy.

Authors:  Pascal Knuefermann; Shu-Ping Shi; Peter Chen; Yashushi Sakata; Georg Baumgarten; Natarajan Sivasubramanian
Journal:  Tex Heart Inst J       Date:  2006

3.  Serum Level of Heart-Type Fatty Acid Binding Protein (H-FABP) Before and After Treatment of Congestive Heart Failure in Children.

Authors:  Amr Zoair; Wegdan Mawlana; Amany Abo-Elenin; Mostafa Korrat
Journal:  Pediatr Cardiol       Date:  2015-06-30       Impact factor: 1.655

Review 4.  Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review.

Authors:  David R Buvat de Virginy
Journal:  Heart Fail Rev       Date:  2006-12       Impact factor: 4.214

5.  Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.

Authors:  O Başar; E Akbal; S Köklü; Y Tuna; E Koçak; N Başar; D Tok; H Erbiş; M Senes
Journal:  Herz       Date:  2013-01-18       Impact factor: 1.443

Review 6.  Biomarkers in heart failure: a clinical review.

Authors:  J Paul Rocchiccioli; John J V McMurray; Anna F Dominiczak
Journal:  Heart Fail Rev       Date:  2008-12-03       Impact factor: 4.214

7.  H-FABP, cardiovascular risk factors, and functional status in asymptomatic spinal cord injury patients.

Authors:  A Akbal; A Kurtaran; B Selçuk; M Akyüz
Journal:  Herz       Date:  2013-03-14       Impact factor: 1.443

8.  Close association between circulating high-sensitivity cardiac troponin I and metabolic syndrome in the general population.

Authors:  Tomonori Sugiura; Yasuaki Dohi; Hiroyuki Takase; Sumiyo Yamashita; Tatsuya Mizoguchi; Satoshi Fujii; Nobuyuki Ohte
Journal:  Hypertens Res       Date:  2019-06-21       Impact factor: 3.872

9.  High sensitive troponin T and heart fatty acid binding protein: novel biomarker in heart failure with normal ejection fraction? A cross-sectional study.

Authors:  Wilfried Dinh; Werner Nickl; Reiner Füth; Mark Lankisch; Georg Hess; Dietmar Zdunek; Thomas Scheffold; Michael Coll Barroso; Klaus Tiroch; Dan Ziegler; Melchior Seyfarth
Journal:  BMC Cardiovasc Disord       Date:  2011-07-05       Impact factor: 2.298

Review 10.  Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence.

Authors:  Abhilash Koratala; Amir Kazory
Journal:  Dis Markers       Date:  2017-06-18       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.